ABIVAX news, videos and press releases
For more news please use our advanced search feature.
ABIVAX - More news...
ABIVAX - More news...
- Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
- Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
- Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
- EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
- EQS-News: Abivax reports 2023 financial results and operational update
- EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
- Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)
- EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
- EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
- EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
- EQS-News: Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
- EQS-News: Abivax 2024 Financial Communication Calendar
- EQS-News: Abivax announces the resumption of its liquidity contract
- EQS-News: Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
- EQS-News: Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
- Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market
- EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
- EQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
- Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris
- Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market
- EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
- Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
- EQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
- Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range
- EQS-News: Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
- Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing
- EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
- Abivax Highlights Obefazimod Ulcerative Colitis Program With New Data to be Presented at the UEG Week 2023
- EQS-News: Abivax files registration statement for proposed initial public offering in the United States
- EQS-News: Abivax announces the release of its 2023 half-year financial report
